FINRA Orders Spartan Capital to Pay $3.18M Over Pre-IPO Atlas Funds

Spartan Capital Securities LLC will pay $2.18 million in restitution to customers and a $1 million fine to settle Financial Industry Regulatory Authority charges that it sold about $24 million of pre-initial public offering private placements issued by funds its former chief executive officer controlled, using offering documents that misrepresented who was charging markups on the deals.
FINRA announced the settlement today. It resolves a disciplinary complaint FINRA’s Department of Enforcement filed Nov. 24, 2025, and was accepted in an order dated Oct. 22. John Lowry, Spartan’s former chief executive officer and majority owner, was suspended from the industry for two years in all capacities and fined $25,000. Kim Monchik, the firm’s former acting chief compliance officer and former chief administrative officer, was barred. Spartan was also censured. The firm, Lowry, and Monchik consented to FINRA’s findings without admitting or denying the allegations.
Between March and October 2021, Spartan made 344 recommendations totaling about $24 million to 186 customers, most of them retail investors, in 16 offerings by three Lowry-controlled private funds: Atlas Fund III LLC, Atlas Fund IV LLC, and Atlas Fund V LLC. Spartan was the sole placement agent and collected a 10% placement fee on each sale, about $2.4 million in total. Atlas Fund Management LLC, which Lowry owns, charged investors a 2% management fee, about $480,000 in total, and a 20% carried interest on any profits.
The Atlas Funds did not hold pre-IPO shares directly. Each offering was a series of one of the funds that bought membership interests in SP Venture Fund 8 LLC, a fund managed by StraightPath Venture Partners LLC that purported to own shares of a single pre-IPO company Lowry selected.
Lowry set the price investors paid, and FINRA found the Atlas Funds marked up 15 of the 16 offerings by 12.75% to 36.4% over what they paid StraightPath, for a total of about $3.25 million. Those markups came on top of the disclosed placement and management fees. In one offering, the Atlas Funds paid a per-share equivalent of $1,450 for interests tied to a pre-IPO company identified only as Company One and sold them to Spartan customers at $1,635.
The offering documents told a different story, FINRA found. The private placement memoranda said a third-party affiliate might sell interests to the Atlas Funds at a markup and that the funds would not share in that profit. Offering supplements said the funds would buy the interests from Iapetus LLC, described as an affiliate of the manager, at a price above what Iapetus had paid. Iapetus, which Lowry formed in February 2021 and of which he is the sole member, never acquired shares for any of the offerings. The Atlas Funds bought directly from StraightPath and applied the markups themselves, and Lowry’s ownership of Iapetus was not disclosed.
FINRA said the misstatements concealed Lowry’s additional compensation and the full extent of his financial interest in the offerings, and gave investors the false impression that a third party had earned the markup by sourcing the shares. It found that Spartan, Lowry, and Monchik violated FINRA Rule 2010, which requires just and equitable principles of trade, by acting in contravention of the anti-fraud provisions of the Securities Act of 1933.
“Spartan failed to conduct reasonable due diligence and, together with its former executives, provided misleading information about markups that benefited entities controlled by its CEO,” said Bill St. Louis, executive vice president and head of enforcement at FINRA.
Monchik spent about 40% of her time running the Atlas entities as their president while serving as Spartan’s acting chief compliance officer, and the only due diligence on the offerings was the review she did for the Atlas Funds, according to FINRA. She did not ask StraightPath for proof that it owned the underlying shares until March 31, 2021, after three offerings had already sold. By the time StraightPath responded on June 15, 2021, the Atlas Funds had sent it about $11.8 million across eight offerings. The documents it provided did not establish that it held the shares, and Spartan went on to sell eight more offerings without further proof. Her research into StraightPath’s manager consisted of limited internet searches and a Lexis search of an unrelated Georgia company called StraightPath Ventures LLC, FINRA found.
FINRA found that Spartan willfully violated Regulation Best Interest, or Reg BI, by recommending the offerings without a reasonable basis and by failing to fully and fairly disclose conflicts tied to Lowry’s ownership of the Atlas entities and Monchik’s dual role. The firm also had no written policies addressing conflicts from affiliated offerings, and Spartan and Monchik failed to establish supervisory procedures for private placement due diligence or to reasonably supervise the offerings.
The U.S. Securities and Exchange Commission sued StraightPath in May 2022, and its funds are now run by a court-appointed receiver. Its founders, Michael Castillero, Brian Martinsen, and Francine Lanaia, were sentenced May 20, 2026, to 11, 10, and eight years in prison, respectively, after a jury convicted them in November 2025 of defrauding investors in the StraightPath funds, including through undisclosed markups. FINRA said that criminal case is unrelated to Spartan and its former executives.
Spartan, a New York-based broker-dealer that has been a FINRA member since 2008, has about 85 registered representatives and about 5,000 retail customer accounts. Spartan terminated Lowry’s and Monchik’s registrations on May 29, 2026.
Both already faced sanctions from earlier FINRA cases. In October 2024, FINRA’s National Adjudicatory Council affirmed findings that Lowry and Monchik failed to disclose customer arbitrations on their registration filings, suspending each for two years and making both statutorily disqualified. All three appealed to the SEC; Lowry and Monchik moved Oct. 22 to withdraw their appeal, citing their settlement with FINRA’s Department of Enforcement, while Spartan’s appeal continues. In March 2026, a FINRA hearing panel found they failed to respond on time to FINRA requests for information and suspended each for two years, a decision they appealed in April to FINRA’s National Adjudicatory Council. Spartan, Lowry, and Monchik also face a separate FINRA complaint, filed in March, alleging fraud tied to Alzamend Neuro private placements and its IPO. Spartan and Monchik are also respondents in a FINRA complaint filed in December 2025 alleging that Spartan churned and excessively traded customer accounts from 2018 to April 2022; Monchik is charged with failing to supervise. In August, FINRA suspended a Spartan broker for excessive trading in a retiree’s account.
FINRA has also brought smaller cases over private placement due diligence this year, including a July settlement in which it censured and fined Brown Associates for ignoring red flags across seven offerings from one sponsor.


